Developing drugs that effectively slow the course of Alzheimer’s disease has been notoriously difficult. Scientists and drug developers believe that a large part of the problem is that they are testing these drugs too late in the progression of the disease, when significant damage to the brain makes intervention much more difficult.

SOURCE